The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...

Sotyktu (deucravacitinib) is a brand-name drug that’s prescribed for moderate to severe plaque psoriasis in certain adults. Sotyktu comes as an oral tablet that’s typically taken once per day.

Sotyktu is not approved to treat rheumatoid arthritis. Adverse Reactions. The safety of Sotytku was assessed in 2 placebo- and active-controlled studies, PSO-1 and PSO-2, ...

Johnson & Johnson JNJ announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trial. Sotyktu ...

Sotyktu helped more people have a clearer scalp compared to apremilast, with 70% of people having a clear or almost clear scalp at 16 weeks vs. 39% of people taking apremilast.

PRINCETON, N.J., May 16, 2024--New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis ...

Sotyktu (deucravacitinib), taken once daily, is the first and only tyrosine kinase 2 (TYK2) inhibitor available for adults with moderate to severe plaque psoriasis.